自身免疫性脑炎患者死亡的影响因素分析

doi:10.20047/j.issn1673-7210.2023.26.18

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (591 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the influencing factors of death in patients with autoimmune encephalitis (AE). Methods Clinical data of 202 patients diagnosed with AE in the First Affiliated Hospital of Zhengzhou University from August 2015 to December 2021 were collected. The patients completed at least six months of follow-up, and were divided into death group (47 cases) and survival group (155 cases) according to their survival during follow-up. The modified Rankin scale (mRS) and clinical assessment scale for AE (CASE) were used to assess the severity of the disease at admission. The clinical data of the two groups were compared, and the influencing factors of death in AE patients were analyzed by logistic regression model. Results There were statistically significant differences in age, seizure, consciousness level, mechanical ventilation, intensive care unit (ICU) admission, deep vein thrombosis, complicated tumor, number of complications, antibody type, mRS score, CASE score, neutrophil/lymphocyte ratio, and monocyte/lymphocyte ratio between the two groups (P＜0.05). Univariate logistic regression analysis showed that age, seizure, consciousness level, mechanical ventilation, ICU admission, deep vein thrombosis, complicated tumor, number of complications, antibody type, mRS score, and CASE score were all influencing factors of death in AE patients (P＜0.05). Further multivariate logistic regression analysis showed that old age, complicated tumor, multiple complications, antibody type γ-aminobutyric acid B-receptor antibody, and CASE score ≥ 10 points on admission were all independent risk factors for death in AE patients (OR＞1, P＜0.05). Conclusion The prognosis of AE patients is affected by many factors such as age, comorbidities, antibody type, etc. Physicians should pay special attention to it in clinical work.

Key words： Autoimmune encephalitis Mortality Influencing factors Antibody type

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yimeng WANG Yaoyao SUN Yidi LIAN Yajun CHENG Xuan

Cite this article:

LI Yimeng WANG Yaoyao SUN Yidi LIAN Yajun CHENG Xuan. Analysis of influencing factors of death in patients with autoimmune encephalitis[J]. 中国医药导报, 2023, 20(26): 86-90.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.26.18 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I26/86

[1] 中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组.中国自身免疫性脑炎诊治专家共识（2022年版）[J].中华神经科杂志，2022，55（9）：931-949.
[2] 于航，李琳琳，倪永清.自身免疫性脑炎患儿认知功能障碍发生情况及相关因素分析[J].中国医药，2023，18（2）：220-223.
[3] 朱艳青，邵恒，钟静玫，等.10例以精神障碍为首发症状的自身免疫性脑炎临床特点分析[J].中国医药科学，2022， 12（10）：197-200.
[4] 傅建梅，陈珉.双重抗体阳性自身免疫性脑炎临床特点及预后分析[J].中国当代医药，2022，29（34）：112-115，119.
[5] Lee WJ，Lee ST，Shin YW，et al. Teratoma Removal，Steroid，IVIG，Rituximab and Tocilizumab（T-SIRT）in Anti-NMDAR Encephalitis [J]. Neurotherapeutics，2021，18（1）：474- 487.
[6] 杨润楠，葛汾汾，蒋静文，等.自身免疫性脑炎患者的临床特征、治疗和预后的回顾性研究[J].四川大学学报（医学版），2022，53（1）：142-148.
[7] 姚东陂，刘鹏，朱吉强，等.抗NMDAR脑炎的临床特点分析[J].中国临床研究，2022，35（1）：70-73.
[8] 林燕妮，梁霞，曾智军，等.抗N-甲基-D-天冬氨酸受体脑炎临床、影像学、脑电图及血清抗体动态观察[J].中国医药科学，2022，12（5）：186-189.
[9] Chi X，Wang W，Huang C，et al. Risk factors for mortality in patients with anti-NMDA receptor encephalitis [J]. Acta Neurol Scand，2017，136（4）：298-304.
[10] Lin J，Li C，Li A，et al. Encephalitis With Antibodies Against the GABA（B）Receptor：High Mortality and Risk Factors [J]. Front Neurol，2019，10：1030.
[11] Lim JA，Lee ST，Moon J，et al. Development of the clinical assessment scale in autoimmune encephalitis [J]. Ann Neurol，2019，85（3）：352-358.
[12] Graus F，Titulaer MJ，Balu R，et al. A clinical approach to diagnosis of autoimmune encephalitis [J]. Lancet Neurol，2016，15（4）：391-404.
[13] Titulaer MJ，McCracken L，Gabilondo I，et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis：an observational cohort study [J]. Lancet Neurol，2013，12（2）：157-165.
[14] Lee WJ，Lee ST，Moon J，et al. Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab：An Institutional Cohort Study [J]. Neurotherapeutics，2016，13（4）：824-832.
[15] Hoftberger R，Titulaer MJ，Sabater L，et al. Encephalitis and GABAB receptor antibodies：novel findings in a new case series of 20 patients [J]. Neurology，2013，81（17）：1500- 1506.
[16] Van Sonderen A，Thijs RD，Coenders EC，et al. Anti-LGI1 encephalitis：Clinical syndrome and long-term follow-up [J]. Neurology，2016，87（14）：1449-1456.
[17] Cai MT，Lai QL，Zheng Y，et al. Validation of the Clinical Assessment Scale for Autoimmune Encephalitis：A Multicenter Study [J]. Neurol Ther，2021，10（2）：985-1000.
[18] Zhang Y，Tu E，Yao C，et al. Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients [J]. Front Immunol，2021，12：796965.
[19] Liu Z，Li Y，Wang Y，et al. The Neutrophil-to-Lymphocyte and Monocyte-to-Lymphocyte Ratios Are Independently Associated With the Severity of Autoimmune Encephalitis [J]. Front Immunol，2022，13：911779.
[20] Sun Y，Ren G，Ren J，et al. The Association Between Age and Prognosis in Patients Under 45 Years of Age With Anti-NMDA Receptor Encephalitis [J]. Front Neurol，2020，11： 612632.
[21] 朱海兵，欧阳桂兰，谢高生，等.老年人自身免疫性脑炎临床特点[J].中国老年学杂志，2021，41（21）：4747-4751.
[22] 张巧漫，王呈泽，马丛丛，等.30例抗γ氨基丁酸B受体脑炎临床特点分析[J].中风与神经疾病杂志，2020， 37（2）：150-153.
[23] Lancaster E，Lai M，Peng X，et al. Antibodies to the GABA（B）receptor in limbic encephalitis with seizures：case series and characterisation of the antigen [J]. Lancet Neurol，2010， 9（1）：67-76.
[24] Gong X，Chen C，Liu X，et al. Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis：A Cohort Study in Western China [J]. Neurol Neuroimmunol Neuroinflamm，2021，8（2）：e958.
[25] Wang W，Li JM，Hu FY，et al. Anti-NMDA receptor encephalitis：clinical characteristics，predictors of outcome and the knowledge gap in southwest China [J]. Eur J Neurol，2016，23（3）：621-629.
[26] Lim JA，Lee ST，Jung KH，et al. Anti-N-methyl-d-aspartate receptor encephalitis in Korea：clinical features，treatment，and outcome [J]. J Clin Neurol，2014，10（2）：157-161.
[27] Irani SR，Bera K，Waters P，et al. N-methyl-D-aspartate antibody encephalitis：temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes [J]. Brain，2010，133（Pt 6）：1655-1667.
[28] Yu J，Yu X，Fang S，et al. The Treatment and Follow-Up of Anti-LGI1 Limbic Encephalitis [J]. Eur Neurol，2016，75（1/2）：5-11.
[29] Schubert J，Bramer D，Huttner HB，et al. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment [J]. Neurol Neuroimmunol Neuroinflamm，2019，6（1）：e514.
[30] Harutyunyan G，Hauer L，Dunser MW，et al. Autoimmune Encephalitis at the Neurological Intensive Care Unit：Etiologies，Reasons for Admission and Survival [J]. Neurocrit Care，2017，27（1）：82-89.